TAKHZYRO® (Lanadelumab-flyo) Injection

TAKHZYRO® is a brand-name medication that contains the active ingredient lanadelumab-flyo. It is primarily used for the prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older. TAKHZYRO® is a monoclonal antibody that inhibits the activity of plasma kallikrein, a key enzyme in the biochemical pathway leading to HAE attacks. By reducing plasma kallikrein's activity, TAKHZYRO® helps prevent HAE attacks.

Indications and Uses

TAKHZYRO® is indicated for the prophylaxis to prevent HAE attacks in individuals aged 12 years and older. It is not used for the treatment of acute HAE attacks. It is intended for subcutaneous administration.

Dosage and Administration

The dosage of TAKHZYRO® is determined by a healthcare provider based on the patient's specific condition. The medication is administered subcutaneously once every two or four weeks. The dose and frequency are individualized to the patient's needs.

Contraindications

TAKHZYRO® should not be used in individuals with known hypersensitivity to lanadelumab-flyo or any of its components. It is essential to discuss any allergies or potential reactions with a healthcare provider.

Adverse Effects and Side Effects

Common side effects of TAKHZYRO® may include:

• Injection site reactions (e.g., pain, redness, swelling).

• Hypersensitivity reactions.

• Serious side effects are rare, but they may include:

• Anaphylaxis (severe allergic reactions).

It is crucial to report any severe or unusual side effects to your healthcare provider.

Storage and Shelf Life

Store TAKHZYRO® in the original carton at 2-8°C (36-46°F) and protect it from light. Do not shake the vial. Keep it out of reach of children. Do not use TAKHZYRO® after the expiration date.

Packaging and Presentation

TAKHZYRO® is available as a solution for subcutaneous injection in vials with various strengths of lanadelumab-flyo.

Regulatory Information

TAKHZYRO® is subject to regulation by health authorities to ensure its safety and efficacy. It is essential to use this medication as directed by a healthcare professional and in accordance with local regulations.

References

Always consult with your healthcare provider and refer to the official prescribing information and product labeling for the most up-to-date and comprehensive information on TAKHZYRO®. Your healthcare provider will guide you in the proper use of this medication, monitor your progress, and tailor the treatment to your specific medical condition.